1.
Factors affecting outcomes in patients reaching end-stage kidney disease worldwide: differences in access to renal replacement therapy, modality use, and haemodialysis practices
by Robinson, Bruce M, Dr
The Lancet (British edition), 2016, Vol.388 (10041), p.294-306

2.
Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure
by Ortiz, Alberto, Prof
The Lancet (British edition), 2014, Vol.383 (9931), p.1831-1843

3.
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis
by Fox, Caroline S, MD
The Lancet (British edition), 2012, Vol.380 (9854), p.1662-1673

4.
A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes
by Niewczas, Monika A
Nature medicine, 2019, Vol.25 (5), p.805-813

5.
Worldwide access to treatment for end-stage kidney disease: a systematic review
by Liyanage, Thaminda, MBBS
The Lancet (British edition), 2015, Vol.385 (9981), p.1975-1982

6.
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis
by Mahmoodi, Bakhtawar K, MD
The Lancet (British edition), 2012, Vol.380 (9854), p.1649-1661

7.
Chronic kidney disease and prevalent atrial fibrillation: The Chronic Renal Insufficiency Cohort (CRIC)
by Soliman, Elsayed Z., MD, MSc, MS
The American heart journal, 2010, Vol.159 (6), p.1102-1107

8.
Dietary Acid Load and Incident Chronic Kidney Disease: Results from the ARIC Study
by Rebholz, Casey M
American journal of nephrology, 2016, Vol.42 (6), p.427-435

9.
Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis...
by Bakris, George L, Dr, Prof
The Lancet (British edition), 2010, Vol.375 (9721), p.1173-1181

10.
In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Co...
by Orchard, T. J
Diabetologia, 2010, Vol.53 (11), p.2312-2319

12.
AKT2 is essential to maintain podocyte viability and function during chronic kidney disease
by Canaud, Guillaume
Nature medicine, 2013, Vol.19 (10), p.1288-1296

13.
Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease
by Group, Sharp Collaborative
The American heart journal, 2010, Vol.160 (5), p.785-794.e10

14.
Chronic kidney disease: the global challenge
by El Nahas, A Meguid
Lancet, 2005, Vol.365 (9456), p.331-340

15.
Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in R...
by Skali, Hicham, MD, MSc
The American heart journal, 2011, Vol.162 (3), p.548-554

16.
Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study
by Zoccali, Carmine
The Lancet (British edition), 2001, Vol.358 (9299), p.2113-2117

17.
The dietary management of calcium and phosphate in children with CKD stages 2-5 and on dialysis—clinical practice recommendation from the Pediatric Renal Nutrition Taskforce
by McAlister, Louise
Pediatric nephrology (Berlin, West), 2019, Vol.35 (3), p.501-518

18.
Arterial stiffness in chronic kidney disease: causes and consequences
by Chue, Colin D
Heart, 2010, Vol.96 (11), p.817-823

19.
Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus
by Fufaa, Gudeta D
Diabetologia, 2014, Vol.58 (1), p.188-198

20.
Effects of self-management on chronic kidney disease: A meta-analysis
by Lin, Mei-Yu
International journal of nursing studies, 2017, Vol.74, p.128-137
